ABSTRACT
Since the introduction of highly active antiretroviral therapy (HAART), the prognosis of HIV-1 disease has significantly changed owing to longer survival expectancy and an improvement in quality of life (Palella et al., 1998). However, given that HIV-1 cannot be eradicated, there are a number of patients over time who have selected resistance mutations associated with reduced susceptibility to one or more drug or drug classes. In the past few years, a number of new antiretroviral drugs and families have been developed, providing new opportunities to build strong salvage regimens for treating HIV-1-infected patients with previous drug failure and reestablish control ofHIV-1 replication (second-wave HAART) (DHHS, 2008).
